IRIS
VITALE, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.558
EU - Europa 11.324
AS - Asia 6.293
SA - Sud America 1.186
Continente sconosciuto - Info sul continente non disponibili 617
AF - Africa 378
OC - Oceania 18
Totale 33.374
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.338
IT - Italia 2.748
GB - Regno Unito 2.700
RU - Federazione Russa 2.038
CN - Cina 1.915
SG - Singapore 1.848
IE - Irlanda 994
BR - Brasile 968
VN - Vietnam 817
UA - Ucraina 597
SE - Svezia 544
FR - Francia 504
HK - Hong Kong 492
DE - Germania 453
FI - Finlandia 336
KR - Corea 300
BD - Bangladesh 277
ZA - Sudafrica 194
IN - India 177
NL - Olanda 115
CA - Canada 105
TR - Turchia 87
AR - Argentina 71
PL - Polonia 62
IQ - Iraq 59
MX - Messico 59
JP - Giappone 54
PK - Pakistan 50
ES - Italia 41
EC - Ecuador 35
NG - Nigeria 32
BE - Belgio 31
CZ - Repubblica Ceca 29
ID - Indonesia 29
KE - Kenya 29
MA - Marocco 29
VE - Venezuela 29
SA - Arabia Saudita 26
AT - Austria 24
CI - Costa d'Avorio 24
CO - Colombia 20
DZ - Algeria 19
CL - Cile 18
PE - Perù 18
UZ - Uzbekistan 18
AE - Emirati Arabi Uniti 17
JO - Giordania 16
AU - Australia 15
EG - Egitto 15
CH - Svizzera 14
IR - Iran 14
JM - Giamaica 14
TN - Tunisia 13
CR - Costa Rica 12
PH - Filippine 12
LT - Lituania 11
GR - Grecia 10
NP - Nepal 10
UY - Uruguay 10
BY - Bielorussia 9
LB - Libano 9
MY - Malesia 9
PY - Paraguay 9
DK - Danimarca 8
IL - Israele 8
AL - Albania 7
HU - Ungheria 7
BO - Bolivia 6
KZ - Kazakistan 6
NO - Norvegia 6
RS - Serbia 6
TT - Trinidad e Tobago 6
BH - Bahrain 5
ET - Etiopia 5
EU - Europa 5
OM - Oman 5
PA - Panama 5
PT - Portogallo 5
RO - Romania 5
AZ - Azerbaigian 4
BA - Bosnia-Erzegovina 4
HN - Honduras 4
PS - Palestinian Territory 4
SN - Senegal 4
TH - Thailandia 4
AO - Angola 3
BG - Bulgaria 3
BW - Botswana 3
CY - Cipro 3
DO - Repubblica Dominicana 3
LV - Lettonia 3
NI - Nicaragua 3
SV - El Salvador 3
TW - Taiwan 3
AM - Armenia 2
CG - Congo 2
CW - ???statistics.table.value.countryCode.CW??? 2
GY - Guiana 2
HR - Croazia 2
KG - Kirghizistan 2
Totale 32.730
Salva come PNG Salva come JPEG
Città #
Southend 2.461
Dallas 1.850
Fairfield 1.216
Singapore 1.037
Ashburn 1.002
Dublin 979
Santa Clara 693
Milan 681
Moscow 568
Woodbridge 567
San Jose 537
Jacksonville 482
Seattle 476
Wilmington 470
Hong Kong 468
Houston 465
Chandler 463
Council Bluffs 450
Cambridge 420
Beijing 419
Hefei 409
Siena 354
Ann Arbor 327
Menlo Park 319
Seoul 295
Rome 285
New York 278
Ho Chi Minh City 247
Princeton 235
The Dalles 214
Los Angeles 211
Hanoi 197
Helsinki 195
Johannesburg 181
Lauterbourg 175
Nanjing 153
Munich 100
Columbus 92
San Mateo 87
Buffalo 86
São Paulo 86
San Diego 75
Dong Ket 73
Dearborn 72
Boardman 66
Florence 59
Orem 59
Nanchang 58
Bengaluru 55
Chicago 53
Düsseldorf 51
Figino 51
Turin 50
Da Nang 47
Redondo Beach 47
Frankfurt am Main 45
Shenyang 45
London 43
Shanghai 43
Bologna 42
Warsaw 38
Tokyo 37
Lappeenranta 36
Washington 33
Brooklyn 32
Haiphong 32
Nuremberg 32
San Francisco 32
Tianjin 32
Abuja 31
Changsha 31
Naples 30
Chennai 29
Guangzhou 29
Rio de Janeiro 29
Izmir 28
Jiaxing 27
Turku 27
Atlanta 25
Brussels 25
Hebei 25
Mexico City 25
Montreal 25
Abidjan 24
Bari 24
Amsterdam 23
Boston 22
Denver 22
Norwalk 22
Phoenix 22
Olomouc 21
Portsmouth 21
Jinan 20
Kraków 20
Toronto 20
Baghdad 19
Stockholm 19
Belo Horizonte 18
Istanbul 18
Kunming 18
Totale 22.307
Salva come PNG Salva come JPEG
Nome #
VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases 914
A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study 413
A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome 365
Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: A four-year follow-up study 357
Adalimumab effectiveness in Behçet’s disease: short and long-term data from a multicenter retrospective observational study 352
Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients 347
Dry eye disease and spondyloarthritis: expanding the spectrum of systemic inflammatory disorders associated with ocular surface disease. Data from the international AIDA Network Spondyloarthritis Registry 327
Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis 323
Auditory involvement in Behcet’s disease: relationship with demographic, clinical, and therapeutic characteristics 322
Ten-Year Retention Rate of Infliximab in Patients with Behçet’s Disease-Related Uveitis 320
A case of resistant adult-onset periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA) syndrome responsive to anakinra. 304
Biological treatments: new weapons in the management of monogenic autoinflammatory disorders 302
Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies 298
Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases: Response to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677–1683 287
Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis 285
Quality of life impairment in Behçet’s disease and relationship with disease activity: a prospective study 281
Certolizumab Pegol treatment in Behcet’s disease with different organ involvement: a multicenter retrospective observational study 281
Behçet’s syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics 275
The diagnostic evaluation of patients with a suspected hereditary periodic fever syndrome: experience from a referral center in Italy 273
Adalimumab-Based Treatment Versus Disease-Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome: A Retrospective Study of Seventy Patients With Vascular Involvement 272
Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: An observational multicentre study 270
Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet’s syndrome 266
Challenges and new horizons in the periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome 265
Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behçet’s Disease 263
Systemic Steroid Sparing Effect of Intravitreal Dexamethasone Implant in Chronic Noninfectious Uveitic Macular Edema 258
Weekly oral alendronate in mevalonate kinase deficiency 248
Correlation of Serum Amyloid-A Levels, Clinical Manifestations, Treatment, and Disease Activity in Patients with Behçet's Disease 247
Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab 246
The eye involvement in monogenic autoinflammatory diseases: Literature review and update 246
The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease 244
Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study 244
Impact of Uveitis on Quality of Life: A Prospective Study from a Tertiary Referral Rheumatology-Ophthalmology Collaborative Uveitis Center in Italy 244
Efficacy and Safety of Adalimumab in Behçet’s disease related uveitis: a multicenter retrospective observational study 240
Orbital/ocular inflammatory involvement in VEXAS syndrome: Data from the international AIDA network VEXAS registry 239
Development and implementation of the AIDA international registry for patients with non-infectious uveitis 236
Diagnostic criteria for adult-onset periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome 235
Clinical and biochemical landmarks in systemic autoinflammatory diseases 233
Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study 233
A patient-driven registry on Behçet’s disease: the AIDA for patients pilot project 230
Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet’s disease 229
Childhood versus adulthood-onset autoinflammatory disorders: myths and truths intertwined 227
Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature 225
Working the endless puzzle of hereditary autoinflammatory disorders. 223
Axial spondyloarthritis in patients with recurrent fever attacks: data from the AIDA network registry for undifferentiated autoInflammatory diseases (USAIDs) 221
Immunometabolic biomarkers of inflammation in Behçet's disease: Relationship with epidemiological profile, disease activity and therapeutic regimes 220
The diagnostic evaluation of patients with potential adult-onset autoinflammatory disorders: our experience and review of the literature 215
Anakinra long-term efficacy and safety in the management of Schnitzler's syndrome and latent tuberculosis infection 214
Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset still disease 214
Critical regulation of Th17 cell differentiation by serum amyloid-A signalling in Behcet's disease 213
Clinical and laboratory features associated with macrophage activation syndrome in Still’s disease: data from the international AIDA Network Still’s Disease Registry 208
Clinical profile and evolution of patients with juvenile-onset Behçet's syndrome over a 25-year period: insights from the AIDA network 208
Development and implementation of the AIDA International Registry for patients with Behçet's disease 208
Treating juvenile idiopathic arthritis (JIA)-related uveitis beyond TNF-α inhibition: a narrative review 208
Long-Term Outcomes of Behçet's Syndrome-Related Uveitis: A Monocentric Italian Experience 206
Correlation between serum amyloid-A and serum levels of proinflammatory cytokines in patients with Behçet's disease 202
Inhibition of Interleukin-1 by Canakinumab as a Successful Mono-Drug Strategy for the Treatment of Refractory Behçet's Disease: A Case Series 200
The hereditary autoinflammatory disorders uncovered 199
Coexistence of axial spondyloarthritis and thromboangiitis obliterans in a young woman 199
Canakinumab as first-line biological therapy in Still’s disease and differences between the systemic and the chronic-articular courses: real-life experience from the international AIDA registry 196
Ultrasound guided corticosteroids sacroiliac joint injections (SIJIs) in the management of active sacroiliitis: a real-life prospective experience 194
Hints for Genetic and Clinical Differentiation of Adult-Onset Monogenic Autoinflammatory Diseases 194
Development and implementation of the AIDA international registry for patients with non-infectious scleritis 192
Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes 192
Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in refractory Behçet disease uveitis and concomitant bladder papillary carcinoma 191
Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues 190
Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives 190
Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study 190
Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study 190
The common NOD2/CARD15 variant P268S in patients with non-infectious uveitis: a cohort study 189
Relapsing Polychondritis: an Update on Pathogenesis, Clinical Features, Diagnostic Tools, and Therapeutic Perspectives 189
Autoinflammatory diseases 189
Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome 189
The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: Clinical manifestations and long-term follow-up 185
Diagnosis and classification of relapsing polychondritis 185
Circulating intercellular adhesion molecule 1 (sICAM-1) in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) 183
Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives 181
Idiopathic inflammatory myopathies: an update on classification and treatment with special focus on juvenile forms 178
Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network 177
Serum amyloid-A in Behçet's disease 177
Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers 177
Efficacy and safety of intravenous immunoglobulin treatment in refractory Behcet's Disease with different organ involvement: a case series 177
Impact of HLA-B51 on Uveitis and Retinal Vasculitis: Data from the AIDA International Network Registries on Ocular Inflammatory Disorders 176
The most recent advances in pathophysiology and management of tumour necrosis factor receptor-associated periodic syndrome (TRAPS): personal experience and literature review 176
Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network 176
Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis 172
Long-term efficacy and safety of anakinra in a patient with Behçet's disease and concomitant tuberculosis infection 171
The role of the F402L allele in the NLRP12-autoinflammatory disorder. Reply to: F402L variant in NLRP12 in subjects with undiagnosed periodic fevers and in healthy controls 171
Adalimumab Monotherapy or Combination Therapy With Methotrexate in Paediatric Uveitis: Data From the AIDA Network Uveitis Registry 170
Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab 170
Serum immunoglobulin D levels in patients with Behçet's disease according to different clinical manifestations 161
Ocular Manifestations in Juvenile Behçet’s Disease: A Registry-Based Analysis from the AIDA Network 160
Successful use of canakinumab in a patient with resistant Behçet's disease 160
Development and Implementation of the AIDA International Registry for Patients With Undifferentiated Systemic AutoInflammatory Diseases 159
The diagnostic role of pathergy test in patients with Behçet’s disease from the Western Europe 159
Development and implementation of the International AIDA Network Castleman’s disease registry 158
Development and implementation of the AIDA International Registry for patients with Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis syndrome 155
Diagnostic role of minor salivary glands biopsy in Sjögren’s syndrome: correlations between histology and autoimmunity in a large, monocentric cohort 155
Comparing biologic options for the management of Behcet's disease-related uveitis 155
Evolving Frontiers in the Treatment of Periodic Fever, Aphthous Stomatitis, Pharyngitis, Cervical Adenitis (PFAPA) Syndrome 155
Paraneoplastic arthritides: an up-to-date case-based systematic review 154
Totale 23.032
Salva come PNG Salva come JPEG
Categoria #
all - tutte 91.215
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 91.215
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.739 0 234 119 134 99 36 82 65 142 232 205 391
2022/20231.806 117 151 245 221 168 342 54 140 210 24 78 56
2023/20241.957 78 47 174 109 96 519 550 82 17 68 65 152
2024/20254.862 263 222 530 271 579 301 219 271 340 233 461 1.172
2025/202612.333 850 1.703 1.512 1.399 1.905 479 1.343 434 403 645 488 1.172
2026/20271.189 703 486 0 0 0 0 0 0 0 0 0 0
Totale 33.374